Dicot reports positive results from study with the drug candidate Libiguin® for the treatment of sexual dysfunctions
Press release: Uppsala, September 14, 2020. Dicot today announces the first results of the animal study conducted together with Pelvipharm. The results show that Dicot's drug candidate Libiguin® had a significant and dose-dependent effect on erection compared to placebo at all measured parameters in Pelvipharm's established animal model. Next steps include further data reviewing with Pelvipharm to optimize the next study in the best way. Pelvipharm SAS is a world-leading preclinical contract laboratory (CRO) specializing in the evaluation of sexual dysfunction in animal models and more